Literature DB >> 23891816

S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: a microdialysis study.

Morris D Faiman1, Swetha Kaul2, Shaheen A Latif3, Todd D Williams4, Craig E Lunte2.   

Abstract

Disulfiram (DSF), used for the treatment of alcohol use disorders (AUDs) for over six decades, most recently has shown promise for treating cocaine dependence. Although DSF's mechanism of action in alcohol abuse is due to the inhibition of liver mitochondrial aldehyde dehydrogenase (ALDH2), its mechanism of action in the treatment of cocaine dependence is unknown. DSF is a pro-drug, forming a number of metabolites each with discrete pharmacological actions. One metabolite formed during DSF bioactivation is S-(N, N-diethylcarbamoyl) glutathione (carbamathione) (carb). We previously showed that carb affects glutamate binding. In the present studies, we employed microdialysis techniques to investigate the effect of carb administration on dopamine (DA), GABA, and glutamate (Glu) in the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), two brain regions implicated in substance abuse dependence. The effect of DSF on DA, GABA, and Glu in the NAc also was determined. Both studies were carried out in male rats. Carb (20, 50, 200 mg/kg i v) in a dose-dependent manner increased DA, decreased GABA, and had a biphasic effect on Glu, first increasing and then decreasing Glu in both the NAc and mPFC. These changes all occurred concurrently. After carb administration, NAc and mPFC carb, as well as carb in plasma, were rapidly eliminated with a half-life for each approximately 4 min, while the changes in DA, GABA, and GLu in the NAc and mPFC persisted for approximately two hours. The maximal increase in carb (Cmax) in the NAc and mPFC after carb administration was dose-dependent, as was the area under the curve (AUC). DSF (200 mg/kg i p) also increased DA, decreased GABA, and had a biphasic effect on Glu in the NAc similar to that observed in the NAc after carb administration. When the cytochrome P450 inhibitor N-benzylimidazole (NBI) (20 mg/kg i p) was administered before DSF dosing, no carb could be detected in the NAc and plasma and also no changes in NAc DA, GABA, and GLu occurred. Changes in these neurotransmitters occurred only if carb was formed from DSF. When NBI was administered prior to dosing with carb, the increase in DA, decrease in GABA, and biphasic effect on GLu was similar to that seen after dosing with carb only. The i p or i v administration of carb showed similar changes in DA, GABA, and GLu, except the time to reach Cmax for DA as well as the changes in GABA, and GLu after i p administration occurred later. The elimination half-life of carb and the area under the curve (AUC) were similar after both routes of administration. It is concluded that carb must be formed from DSF before any changes in DA, GABA, and GLu in the NAc and mPFC are observed. DSF and carb, when administered to rats, co-release DA, GABA, and GLu. Carb, once formed can cross the blood brain barrier and enter the brain. Although inhibition of liver ALDH2 is the accepted mechanism for DSF's action in treating AUDs, the concurrent changes in DA, GABA, and GLu in the NAc and mPFC after DSF administration suggest that changes in these neurotransmitters as a potential mechanism of action not only for AUDs, but also for cocaine dependence cannot be excluded.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbamathione; Disulfiram; Dopamine; GABA; Glutamate; Microdialysis

Mesh:

Substances:

Year:  2013        PMID: 23891816      PMCID: PMC4631046          DOI: 10.1016/j.neuropharm.2013.07.007

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  72 in total

Review 1.  Drugs of abuse and the brain.

Authors:  A I Leshner; G F Koob
Journal:  Proc Assoc Am Physicians       Date:  1999 Mar-Apr

2.  INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY DISULFIRAM.

Authors:  M GOLDSTEIN; B ANAGNOSTE; E LAUBER; M R MCKEREGHAM
Journal:  Life Sci (1962)       Date:  1964-07

3.  Inhibition of hexokinase by disulfiram and diethyldithiocarbamate.

Authors:  J H STROMME
Journal:  Biochem Pharmacol       Date:  1963-02       Impact factor: 5.858

4.  Effects of diethyldithiocarbamate and disulfiram on glucose metabolism and glutathione content of human erythrocytes.

Authors:  J H STROMME
Journal:  Biochem Pharmacol       Date:  1963-07       Impact factor: 5.858

Review 5.  The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?

Authors:  R Christopher Pierce; Vidhya Kumaresan
Journal:  Neurosci Biobehav Rev       Date:  2005-08-11       Impact factor: 8.989

6.  Pathological gambling is linked to reduced activation of the mesolimbic reward system.

Authors:  Jan Reuter; Thomas Raedler; Michael Rose; Iver Hand; Jan Gläscher; Christian Büchel
Journal:  Nat Neurosci       Date:  2005-01-09       Impact factor: 24.884

Review 7.  Medications development: successes and challenges.

Authors:  Frank Vocci; Walter Ling
Journal:  Pharmacol Ther       Date:  2005-10       Impact factor: 12.310

8.  Glutamate-dopamine cotransmission and reward processing in addiction.

Authors:  Christopher C Lapish; Jeremy K Seamans; L Judson Chandler
Journal:  Alcohol Clin Exp Res       Date:  2006-09       Impact factor: 3.455

9.  Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens.

Authors:  Florence Razoux; René Garcia; Isabelle Léna
Journal:  Neuropsychopharmacology       Date:  2006-03-08       Impact factor: 7.853

10.  Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation.

Authors:  A Madan; A Parkinson; M D Faiman
Journal:  Alcohol Clin Exp Res       Date:  1998-09       Impact factor: 3.455

View more
  6 in total

1.  N-acetyl-S-(N,N-diethylcarbamoyl) cysteine in rat nucleus accumbens, medial prefrontal cortex, and in rat and human plasma after disulfiram administration.

Authors:  Robert D Winefield; Anthonius A M Heemskerk; Swetha Kaul; Todd D Williams; Michael J Caspers; Thomas E Prisinzano; Elinore F McCance-Katz; Craig E Lunte; Morris D Faiman
Journal:  J Pharm Biomed Anal       Date:  2015-01-25       Impact factor: 3.935

2.  Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels.

Authors:  Patricia Di Ciano; Daniel F Manvich; Abhiram Pushparaj; Andrew Gappasov; Ellen J Hess; David Weinshenker; Bernard Le Foll
Journal:  Psychopharmacology (Berl)       Date:  2017-10-30       Impact factor: 4.530

3.  Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial.

Authors:  Sulggi A Lee; Julian H Elliott; James McMahon; Wendy Hartogenesis; Namandje N Bumpus; Jeffrey D Lifson; Robert J Gorelick; Peter Bacchetti; Steven G Deeks; Sharon R Lewin; Radojka M Savic
Journal:  Clin Pharmacol Ther       Date:  2018-10-09       Impact factor: 6.875

4.  Challenges of simultaneous measurements of brain extracellular GABA and glutamate in vivo using enzyme-coated microelectrode arrays.

Authors:  Jason J Burmeister; David A Price; François Pomerleau; Peter Huettl; Jorge E Quintero; Greg A Gerhardt
Journal:  J Neurosci Methods       Date:  2019-10-07       Impact factor: 2.390

5.  Serotonin-2C receptor agonists decrease potassium-stimulated GABA release in the nucleus accumbens.

Authors:  James M Kasper; Raymond G Booth; Joanna Peris
Journal:  Synapse       Date:  2014-11-20       Impact factor: 2.562

Review 6.  Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment.

Authors:  Robin C Wackernah; Matthew J Minnick; Peter Clapp
Journal:  Subst Abuse Rehabil       Date:  2014-01-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.